AGIO Agios Pharmaceuticals Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Agios Pharmaceuticals, Inc. and Certain Officers and Directors

NEW YORK--(BUSINESS WIRE)--

Levi & Korsinsky, LLP announces that it has commenced an investigation of Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) (NASDAQ:AGIO) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.

At the December 2016 American Society of Hematology meeting, Agios presented new data for its AG-519 molecule, which is in development for treatment of pyruvate kinase deficiency. Agios reported for AG-519 that after the data cut-off, one ongoing serious adverse event of drug related cholestatic hepatitis was reported after a dose of 300 mg.

On December 5, 2016, following this news, Agios stock fell over 12% to close at $49.88. To obtain additional information about the investigation, go to:

http://zlk.9nl.com/Agios_AGIO

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
06/12/2016

Underlying

AGIOAgios Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agios Pharmaceuticals Inc.

 PRESS RELEASE
Free
AGIO Agios Pharmaceu...

U.S. FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Ane...

U.S. FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemiaMarketed under AQVESME brand name in the U.S. for thalassemia indication; PYRUKYND® (mitapivat) remains the U.S. brand name for PK deficiency indication AQVESME expected to be available in late January 2026, following AQVESME REMS program implementationCompany will host investor conference call and webcast tomorrow, December 24 at 8:00 a.m....

December 24, 2025 1 EN
 PRESS RELEASE
Free
AGIO Agios Pharmaceu...

Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia

Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has not yet issued a regulatory decision on the supplemental New Drug Application (sNDA) for mitapivat for the treatment of adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia and that the sNDA remains ...

December 8, 2025 1 EN
 PRESS RELEASE
Free
AGIO Agios Pharmaceu...

Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapiva...

Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect bilirubin Trial showed trend favoring mitapivat but did not meet statistical significance in primary endpoint of annualized rate of SCPCs (pain crises), and the key secondary endpoint of change from baseline in PROMIS Fatigue was not met Patients in the mitapivat arm who achieved hemoglobin response had clinically meaningful benefits in SCPC-related endpo...

November 19, 2025 1 EN
 PRESS RELEASE
Free
AGIO Agios Pharmaceu...

Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th AS...

Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that new data on mitapivat, an oral pyruvate kinase (PK) activator, will be featured in oral and poster presentations during the 67th American Society of Hematology (ASH) Annual Meeting and Exposition (ASH 2025) in Orlando, Florida, December 6-9, 2025. “This ...

November 3, 2025 1 EN
 PRESS RELEASE
Free
AGIO Agios Pharmaceu...

Agios Reports Third Quarter 2025 Financial Results and Provides Busine...

Agios Reports Third Quarter 2025 Financial Results and Provides Business Update $12.9 million in third quarter PYRUKYND® (mitapivat) net revenuesPDUFA goal date for PYRUKYND U.S. sNDA in thalassemia set for December 7, 2025CHMP adopted positive opinion for PYRUKYND in thalassemia; EC decision expected by early 2026RISE UP Phase 3 trial topline results in sickle cell disease by year-end; potential U.S. commercial launch in 2026Phase 2b tebapivat trial in lower-risk MDS fully enrolled; topline results expected in early 2026$1.3 billion dollars in cash, cash equivalents and marketable securiti...

October 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch